ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 183

A Strong Association Between HLA-A*26 and Behçet’s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet’s Syndrome

Tatsuo Kobayashi1, Mitsumasa Kishimoto2, Kazuki Yoshida1, Yuri Ohara3, Hiroto Nakano1, Masahiro Minoda1, Hideto Oshikawa1 and Kazuo Matsui1, 1Rheumatology, Kameda Medical Center, Kamogawa City, Chiba, Japan, 2Division of Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 3Allergy and Rheumatology, St. Luke's International Hospital, Chuo-ku, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Japanese and human leukocyte antigens (HLA)

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose: An association between Behçet’s Syndrome (BS) and HLA-B*51 is widely reported among many different ethnic groups. Recently, a few reports from Taiwan, Greece and Japan were published that indicated HLA-A*26 is also associated with BS independently from HLA-B*51, but these studies may have some limitations. These limitations include small numbers, were not written in English, only analyzed BS with ocular lesions, or were mainly led by ophthalmologists. Therefore, the association between HLA-A*26 and BS still remains unclear. For this report we studied phenotype frequencies (PF) of HLA-A and HLA-B in Japanese BS patients seen by not only ophthalmologists but also experts in different specialties, mainly rheumatologists. 

Methods :  All BS patients seen at tertiary care centers of Kameda Medical Center and St. Luke’s International Hospital in Japan between 2003-2012 were included in the analysis. Patients were mainly seen by rheumatologists, followed by neurologists, dermatologists, ophthalmologists, and gastroenterologists. The diagnosis of BS was made on clinical manifestation and expert opinions. Charts were reviewed for DNA typing of HLA alleles and disease manifestations. To compare PF, we adopted data from the central bone marrow data center registry of Japanese Red Cross Society (n=263016) as a control for the general population in Japan. The significance of the distribution of phenotypes was analyzed by one-sample proportions test and the primary P-values were corrected by using the Bonferroni correction (Pc). We analyzed manifestations by Fisher’s exact probability test or t-test. 

Results : As for HLA-A and HLA-B, 80 and 81 patients were tested respectively (88 patients were eligible for HLA-B*51 analysis) and 6 HLA-A and 19 HLA-B alleles were detected. Of all, PF of HLA-A*26 was significantly higher than the general Japanese population (42.5% vs. 22.6%, Pc=8.0 x10-4). The same is true for HLA-B*51 (44.3% vs. 17.1%, Pc=7.1×10-10). No significant differences were seen in other HLA alleles. Secondly, we analyzed the difference in manifestations of BS patients stratified by HLA-A*26 or HLA-B*51. No significant difference was seen except for age of onset, which was younger in patients with HLA-B*51 than without it (mean±SD (years): 34.1±13.6 vs. 41.3±17.9, P=0.041). There is also a tendency that gastrointestinal (GI) lesions are less likely for patients with HLA-B*51 (28.2% vs. 46.9%, P=0.082). We detected no significant difference of manifestations between HLA-A*26 positive patients and negative patients.

Conclusion: HLA-A*26 is found to be alleles for BS susceptibility among BS patients not only with ocular lesions but also various manifestations in Japan. Moreover, our study also showed that patients with HLA-B*51 have younger onset and a lower tendency of GI lesions.

Table 1: Phenotype frequency of HLA-A and HLA-B in BS patients compared with the general population in Japan (extracted data were shown)

 

PF of BS patients (%)

PF of the general Japanese (%)

P-value

Pc-value

HLA-A*02

46.3

42.9

0.62

 

-A*24

58.8

60.1

0.83

 

-A*26

42.5

22.6

3.6 x10-5

8.0 x10-4

-A*33

58.8

60.1

0.06

 

HLA-B*51

44.3

17.1

3.2×10-11

7.1x10-10

-B*52

16.1

21.0

0.34

 

-B*54

16.1

14.6

0.83

 


Disclosure:

T. Kobayashi,
None;

M. Kishimoto,
None;

K. Yoshida,
None;

Y. Ohara,
None;

H. Nakano,
None;

M. Minoda,
None;

H. Oshikawa,
None;

K. Matsui,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-strong-association-between-hla-a26-and-behcets-syndrome-in-japanese-patients-from-two-center-cohort-study-of-behcets-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology